- $19.98m
- $20.33m
- $48.67m
- 40
- 36
- 32
- 28
Annual income statement for IRIDEX, fiscal year end - December 28th, USD millions except per share, conversion factor applied.
2021 January 2nd | 2022 December 31st | 2022 January 1st | 2023 December 30th | 2024 December 28th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 36.3 | 57 | 53.9 | 51.9 | 48.7 |
| Cost of Revenue | |||||
| Gross Profit | 15.6 | 25.4 | 22.8 | 21.8 | 19.5 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 42.9 | 64.5 | 58.9 | 61.9 | 57 |
| Operating Profit | -6.58 | -7.54 | -5.03 | -10 | -8.3 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.3 | -7.48 | -5.18 | -9.48 | -8.84 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.33 | -7.55 | -5.22 | -9.57 | -8.91 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.33 | -7.55 | -5.22 | -9.57 | -8.91 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.33 | -7.55 | -5.22 | -9.57 | -8.91 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.457 | -0.474 | -0.444 | -0.593 | -0.542 |